SHIVA GUPTA to Treatment Outcome
This is a "connection" page, showing publications SHIVA GUPTA has written about Treatment Outcome.
Connection Strength
0.082
-
Tumor response criteria for assessing pazopanib first-line therapy in patients with metastatic renal cell carcinoma (mRCC). Abdom Radiol (NY). 2020 06; 45(6):1872-1882.
Score: 0.040
-
Interferon-beta-1b effects on re-enhancing lesions in patients with multiple sclerosis. Mult Scler. 2005 Dec; 11(6):658-68.
Score: 0.015
-
Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma. J Pharmacol Exp Ther. 2017 11; 363(2):136-147.
Score: 0.008
-
Staging, surveillance, and evaluation of response to therapy in renal cell carcinoma: role of MDCT. Abdom Imaging. 2014 Feb; 39(1):66-85.
Score: 0.006
-
Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: a double-blind, placebo controlled, crossover study. Clin Neuropharmacol. 2009 Jan-Feb; 32(1):41-7.
Score: 0.005
-
Heterogeneity in response to interferon beta in patients with multiple sclerosis: a 3-year monthly imaging study. Arch Neurol. 2009 Jan; 66(1):39-43.
Score: 0.004
-
Effects of interferon beta-1b on black holes in multiple sclerosis over a 6-year period with monthly evaluations. Arch Neurol. 2005 Nov; 62(11):1684-8.
Score: 0.004